Functional Concept
Novo Nordisk Terminates Development of Kidney Disease Drug Ocedurenone After Phase 3 Failure
Novo Nordisk, ocedurenone, kidney disease, hypertension, Phase 3 trial, CLARION-CKD, drug development failure
FDA Authorizes LumiThera’s Valeda Light Delivery System for Dry AMD Treatment
FDA authorization, Valeda Light Delivery System, dry AMD treatment, photobiomodulation, LumiThera
CMS Approves Transitional Pass-Through Payments for Renal Denervation Systems from Medtronic and Recor Medical
Renal Denervation Systems, CMS, Transitional Pass-Through Payments, Medtronic, Recor Medical, Hypertension Treatment
Viking Therapeutics’ Oral Weight Loss Drug VK2735 Shows Promising Phase 1 Results
VK2735, Viking Therapeutics, oral weight loss drug, GLP-1/GIP dual agonist, obesity treatment, Phase 1 trial results
Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes
Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.
Journey Medical’s Emrosi Receives FDA Approval, Setting New Standard for Rosacea Treatment
Rosacea treatment, Emrosi, FDA approval, Minocycline hydrochloride, Journey Medical Corporation, Dermatological conditions, New standard of care
FDA Announces Availability of All Doses of Novo Nordisk’s Ozempic and Wegovy
FDA, Novo Nordisk, Ozempic, Wegovy, drug shortage, semaglutide, obesity treatment, type 2 diabetes treatment
Spero Therapeutics Slashes 39% of Workforce Following Phase 2 Antibiotic Trial Failure
Spero Therapeutics, antibiotic trial failure, workforce reduction, biotech layoffs, cash runway extension
Novartis Secures FDA Approval for Scemblix as First-Line Treatment for Newly Diagnosed CML, Anticipates $3B in Peak Sales
Novartis, Scemblix, FDA Approval, First-Line Treatment, CML, Chronic Myeloid Leukemia, ASC4FIRST Trial, Tyrosine Kinase Inhibitors, STAMP Inhibitor
Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients
Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction